{"nctId":"NCT03138603","briefTitle":"Metoprolol to Reduce Perioperative Myocardial Injury","startDateStruct":{"date":"2016-12","type":"ACTUAL"},"conditions":["Heart Diseases"],"count":72,"armGroups":[{"label":"Metoprolol","type":"EXPERIMENTAL","interventionNames":["Drug: Metoprolol Tartrate"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Metoprolol Tartrate","otherNames":["Beta-blocker"]},{"name":"Placebo","otherNames":["Sham","Placebo-comparator","Control"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n1. Age \\>= 50 years\n2. Beta-blocker naïve \\[30 days prior to surgery\\]\n3. Previously diagnosed coronary artery disease (CAD), or\n\n   1. History of peripheral vascular disease (PVD), or\n   2. Chronic kidney disease (CKD) \\[eGFR ≤60ml/min\\], or\n   3. History of positive stress test or\n   4. At high risk for CAD (must meet at least 2 criteria):\n\n   i. Age \\>= 70 years ii. Hypertension iii. Diabetes requiring oral medication or insulin iv. Current smoker or some days smoker within the past 2 years\n4. Major non-cardiac, elective surgery under general anesthesia\n\nExclusion Criteria\n\nSubjects will not be enrolled if any of the following criteria exist:\n\n1. History of stroke, or transient ischemic attack (TIA)\n2. Previously diagnosed carotid disease, i.e., either 70% unilateral or 50% bilateral carotid occlusion.\n3. Heart rate \\<=55bpm\n4. Congestive heart failure with New York Heart Association(NYHA) Functional Classification of III-IV or left ventricular heart failure with ejection fraction ≤50%\n5. Severe valvular regurgitation\n6. Second or third degree atrioventricular (AV) block without pacemaker\n7. Active asthma or chronic obstructive pulmonary disease (COPD) with symptoms or resolving symptoms on day of surgery\n8. Anemia \\[HB\\<=9g/dL\\]\n9. Allergy to beta-blockade drugs\n10. Unwilling or unable to give consent for participation\n11. Undergoing any carotid endarterectomy, endovascular, endoscopic, superficial, or ambulatory procedures\n12. Pregnancy or lactating women\n13. Prisoners","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Effectiveness of Beta-blocker Therapy Reducing Post-operative Myocardial Injury","description":"Measured effectiveness of post-operative beta-blocker therapy to reduce myocardial injury by monitoring daily biomarkers (High-Sensitivity cardiac Troponin \\[HS-cTn\\]).\n\nDaily post-operative biomarker (hs-cTn) measurements to determine myocardial injury.\n\nMyocardial injury is defined as a new hscTn elevation \\>99th percentile, or a 50% increase if the baseline hscTn is already elevated \\>99th percentile","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Effectiveness in Reduction of Major Adverse Cardiac Events (MACE)","description":"MACE are defined as myocardial ischemia (MI), cardiac death or coronary revascularization","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Monitor Post-operative Myocardial Ischemia","description":"Post-operative cardiac monitoring via ECG to evaluate if myocardial ischemia is present.\n\nMyocardial Ischemia is defined as ST depression or elevation of ≥0.2 mV in one lead or ≥0.1 mV in two contiguous leads lasting ≥10 min","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Stroke Related Events Following Surgery","description":"Stroke will be defined as focal or global cerebral, spinal, or retinal dysfunction of sudden onset","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Having Vasopressor Therapy to Regulate Symptomatic Hypotension","description":"Monitor participants with vasopressor requirements for blood pressure regulation due to symptomatic hypotension (rate/duration time).\n\nSymptomatic hypotension (systolic BP \\< 90 mmHg) can be determined by clinical intervention due to low blood pressure and/or patient developed clinical symptoms due to hypotension.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participant Incidence of Clinically Relevant Bradycardia","description":"Monitored participants with cumulative events of bradycardia (rate/duration time).\n\nBradycardia is defined as low heart rate (HR \\< 50/min).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Number of Days Spent Post-operative Hospitalization","description":"Measurement of participants number of days spent hospitalized (0-3 days) following surgery.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Recovery Progress Events at 30-days Post-operative.","description":"Measured number of participant post-operative recovery events, 30-days following the surgical procedure.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Participant Post-operative Mortality at 1-year Following Surgery","description":"Measured number of patient post-operative mortality at 1-year.\n\nMeasured by 'living', 'deceased', 'date of death'.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Measured Number of Patient Adverse Events","description":"Number of measured participant adverse events and severity associated with low blood pressure (hypotension), low heart heart (bradycardia), nausea and vomiting; or other symptoms determined 'probably', 'possibly', 'unrelated', or 'related' to the study intervention. This includes any unplanned escalation of care admissions (e.g., Intensive Care Unit \\[ICU\\]).\n\nStudy patient safety is monitored by the investigators (MD) with experience in critical care anesthesia, as well as an experienced clinical research team responsible for data collection and reporting of events.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":34},"commonTop":["Hypotension event","Bradycardia Event"]}}}